Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
73.54 EUR | +0.42% |
|
-0.84% | +5.16% |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 30.29 times its estimated earnings per share for the ongoing year.
- The company's enterprise value to sales, at 3.14 times its current sales, is high.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Diversified Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+5.16% | 33.23B | - | ||
+11.85% | 79.93B | B | ||
-7.86% | 43.46B | A- | ||
+14.63% | 18.7B | B | ||
+6.60% | 11.26B | A- | ||
-23.67% | 9.96B | B | ||
-11.25% | 9.55B | - | ||
+0.38% | 8.76B | A- | ||
-3.57% | 8.41B | C- | ||
+5.43% | 7.97B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- DD Stock
- DDPN Stock
- Ratings DuPont de Nemours, Inc.